Financial Services

Merging onto Nasdaq, RTB Digital's 'Roundtable' platform aims to protect creators and upend the $200B media market with a bold 'Web4' vision.

With a new tech-first TPO channel, GO Mortgage claims it will replace, not just compete with, the outdated systems plaguing mortgage brokers.

Chinese giant Changan targets a top-5 MEA market rank by 2030, shifting from exports to deep local investment with its ambitious Vast Ocean Plan 2.0.

Tired of flight delays and fragile supply chains? New MIT research reveals how companies can be both hyper-efficient and incredibly resilient.

As Quebecor prepares for its annual meeting, a look at its strong 2025 results, aggressive telecom expansion, and strategy to challenge Canada's giants.

McDonald's enters the stadium naming game with a massive community pledge for Chicago, but not all residents are cheering for the new riverfront project.

Fourier and Intel reveal how modular, liquid-cooled systems are replacing components to power the next wave of AI, making deployment speed the ultimate weapon.

Intense competition and NHS staff shortages are pushing thousands of qualified British students to pursue medical degrees at international universities.

A new report finds a "U-shaped" recovery where the richest and poorest schools improve, but the middle lags. A pre-pandemic "learning recession" persists.

China's Weichai Power has earned a top global quality award, a first for its industry, signaling a major shift in high-end manufacturing standards.

The German insurer posts a record €4.5B Q1 profit, leveraging AI and strong P&C results to navigate a volatile market and boost shareholder returns.

HireQuest's persistent $105M cash offer for TrueBlue's on-demand arm puts the staffing giant at a crossroads, fueling speculation of a sector shake-up.

Veteran wealth architect Dr. Anna Maria Panasiuk brings her billion-dollar asset protection expertise to the prestigious Forbes Finance Council.

Despite a Q3 net loss from market volatility and one-off costs, the energy firm declared its 51st straight dividend, banking on new acquisitions for growth.

With its first patient enrolled and key EU approvals, Inhibikase pushes its PAH drug IKT-001 forward, balancing clinical hope with financial realities.

Andersen Group reports a 15.7% revenue jump, but IPO-related costs mask strong operational performance as the firm pursues aggressive global expansion.

After two rejections and a dramatic financial restructuring, Atara Biotherapeutics has a clear path to resubmit its key cancer therapy to the FDA.

With cash to last into 2027, Bolt Biotherapeutics focuses all hope on its lead cancer drug, BDC-4182, ahead of crucial Q3 clinical data.

After 18 years, a judge ruled prosecutors hid key scientific evidence in the case of Deborah Nicholls, convicted of a fire that killed her three children.

A new report reveals staggering youth joblessness, especially for Black teens in Chicago, framing it as a long-ignored policy failure requiring urgent action.